Loading clinical trials...
Loading clinical trials...
The reason for this study is to determine the recommended phase 2 dose of the study drug LY3295668 erbumine in participants with breast cancer that has spread to other parts of the body.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Eli Lilly and Company
NCT06994377 · Metastatic Breast Cancer
NCT07222215 · Estrogen-receptor-positive Breast Cancer, Metastatic Breast Cancer, and more
NCT02422641 · Metastatic Breast Cancer, Leptomeningeal Disease
NCT06110793 · Metastatic Breast Cancer
NCT06525766 · Anatomic Stage IV Breast Cancer AJCC v8, Estrogen-receptor-positive Breast Cancer, and more
City of Hope National Medical Center
Duarte, California
Dana Farber Cancer Institute
Boston, Massachusetts
South Texas Accelerated Research Therapeutics, LLC
San Antonio, Texas
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions